Long-term Response to First-line Pazopanib Therapy in mRCC Patients: A Multicenter Italian Experience.
BACKGROUND/AIM
The specific characteristics of patients who are most likely to benefit from pazopanib therapy are still uncertain. We report on the results of an Italian multicenter, retrospective analysis investigating the factors associated with longer response to first-line pazopanib in patients with metastatic renal cell carcinoma.


PATIENTS AND METHODS
Adult patients were considered if they had received treatment with pazopanib (800 mg/day) for >12 months in the first-line setting.


RESULTS
In total, 112 patients were evaluated. Median duration of pazopanib treatment was 22.6 months (IQR 17.8 months). Median PFS was 22.6 months (95%CI= 20.2-25.0). Eighty-three patients (74.1%) had a PFS ≥18 months. Median OS was 32.9 months (95%CI=30.2-35.6). At statistical analysis, only PS score (1+ vs. 0) was significantly associated with PFS (HR=1.76; 95%CI=1.02-3.05; p=0.04).


CONCLUSION
Pazopanib therapy may be suitable for all patients with mRCC, and especially in those with PS 0.
['Sbrana|Andrea|A|', 'Biasco|Elisa|E|', 'Paolieri|Federico|F|', 'Palesandro|Erica|E|', 'Caserta|Claudia|C|', 'Iacovelli|Roberto|R|', 'Detti|Beatrice|B|', 'Santini|Daniele|D|', 'Mosca|Alessandra|A|', 'Morelli|Franco|F|', 'Fornarini|Giuseppe|G|', 'De Giorgi|Ugo|U|', 'Masini|Cristina|C|', 'Galli|Luca|L|']
D000328:Adult D000368:Aged D000369:Aged, 80 and over D020533:Angiogenesis Inhibitors D002292:Carcinoma, Renal Cell D018572:Disease-Free Survival D005260:Female D006801:Humans D007191:Indazoles D007558:Italy D007680:Kidney Neoplasms D008297:Male D008875:Middle Aged D011743:Pyrimidines D040262:Receptors, Vascular Endothelial Growth Factor D012189:Retrospective Studies D013449:Sulfonamides
response first-line pazopanib mRCC